Mycozole/Mycozole IV Drug Interactions

Mycozole: Rifampicin: decreased plasma concentrations of fluconazole.
Hydrochlorothiazide: increased plasma concentrations of fluconazole.
Fluconazole may interfere with the metabolism of some drugs if given concomitantly, mainly through inhibition of the cytochrome P450 enzymes CYP3A4 and CYP2C9. This may account for the reported increases in plasma concentrations of bosentan, ciclosporin, midazolam, nevirapine, amitriptyline, phenytoin, rifabutin, sulfonylurea hypoglycaemics and nateglinide.
Selective cyclo-oxygenase-2-inhibitors such as celecoxib and parecoxib, tacrolimus, triazolam, warfarin, and zidovudine: fluconazole may inhibit the formation of a toxic metabolite of sulfamethoxazole.
Terfenadine, astemizole and cisapride: increased concentrations following high doses of fluconazole have been associated with ECG abnormalities and toxicity. Therefore, the use of these drugs with fluconazole should be avoided because of the risk of cardiac arrhythmias.
Amitriptyline: syncope attributed to increased amitriptyline concentrations has occurred when amitriptyline was given with fluconazole.
Theophylline: may reduce its clearance when given with fluconazole.
Contraceptive steroids: its concentrations may be increased in patients given with fluconazole and the efficacy of oral contraceptives may be affected.
Mycozole IV: In general, fewer interactions are considered to occur with fluconazole than with either itraconazole or ketoconazole. Use of rifampicin with fluconazole results in reduced plasma concentrations of fluconazole. Use of hydrochlorothiazide and fluconazole has resulted in clinically insignificant increases in plasma fluconazole concentrations. Fluconazole may interfere with the metabolism of some other drugs mainly through inhibition of the cytochrome P450 isoenzymes CYP3A4 and CYP2C9. This may account for the reported increases in plasma concentrations of bosentan, ciclosporin, midazolam, nevirapine, amitriptyline, nortriptylinr, phenytoin, rifabutin, sulfonylurea hypoglycaemics and nateglinide, selective cyclo-oxygenase-2-inhibitors such as celecoxib and parecoxib, tacrolimus, triazolam, warfarin, and zidovudine; amitfluconazole may inhibit the formation of a toxic metabolite of sulfamethoxazole.
Increase in terfenadine concentrations following high doses of fluconazole have been associated with ECG abnormalities. A similar effect may be anticipated with astemizole. Use of fluconazole with cisapride could result in increased cisapride concentrations and associated toxicity. The use of fluconazole with astemizole, cisapride, or terfenadine should therefore be avoided because of the risk of cardiac arrhythmias. Syncope attributed to increased amitriptyline concentrations has occurred when amitriptyline was given with fluconazole. Fluconazole may also reduce the clearance of theophylline. The concentration of contraceptive steroids has been reported to be both increased and decreased in patients receiving fluconazole and the efficacy of oral contraceptives may be affected.